Background: Roux-en-Y gastric bypass (RYGB) surgery results in exaggerated postprandial insulin and incretin responses and increased susceptibility to hypoglycemia. Objective: We examined whether these features are due to caloric restriction (CR) or altered nutrient handling. Methods: We performed comprehensive analysis of postprandial metabolite responses during a 2-hour mixed-meal tolerance (MMT) test in 20 morbidly obese subjects with type 2 diabetes who underwent RYGB surgery or matched CR. Acylcarnitines and amino acids (AAs) were measured using targeted mass spectrometry. A linear mixed model was used to determine the main effect of interventions and interaction term to assess the effect of interventions on postprandial kinetics. Results: Two weeks after these interventions, several gut hormones (insulin, glucose-dependent insulinotropic polypeptide, and glucagon-like peptide 1), glucose, and multiple AAs, including branched-chain and aromatic species, exhibited a more rapid rate of appearance and clearance in RYGB surgery subjects than in CR subjects during the MMT test. In the RYGB surgery group, changes in leucine/isoleucine, methionine, phenylalanine, and glucagon-like peptide 1 response were associated with changes in insulin response. Levels of alanine, pyruvate, and lactate decreased significantly at the later stages of meal challenge in RYGB surgery subjects but increased with CR. Conclusions: RYGB surgery results in improved metabolic flexibility (ie, greater disposal of glucose and AAs and more complete β-oxidation of fatty acids) compared with CR. The changes in the AA kinetics may augment the hormonal responses seen after RYGB surgery. The reduction in key gluconeogenic substrates in the postprandial state may contribute to increased susceptibility to hypoglycemic symptoms in RYGB surgery subjects.
R oux-en-Y gastric bypass (RYGB) surgery results in improvement in glucose homeostasis before significant weight loss. 1 Besides a smaller gastric pouch that enforces caloric restriction (CR), RYGB surgery rearranges the gut anatomy such that the shorter intestinal nutrient transit significantly alters several gut hormonal responses. 2, 3 In particular, the insulin and incretin responses are unequivocally accentuated with meals after RYGB surgery but not after equivalent CR weight loss. 4 Importantly, a larger incretin response is observed when a meal is administered via the alimentary limb than by administration into the bypassed gastric remnant, thus corroborating the "hindgut hypothesis." 5 Increased incretin response is posited to contribute to hyperinsulinemia seen in RYGB surgery subjects 6 and has been proposed to mediate expansion of β-cell mass that contributes to postsurgical hyperinsulinemic hypoglycemia. 7, 8 In contrast to the widely described hormonal responses, much less is known about metabolite responses after different weight loss interventions. Whereas fasting metabolite levels are informative, postprandial metabolite responses are related to insulin action along multiple physiological axes 9 and might provide an indication of changes in metabolic flexibility after an intervention. 10 Several studies have shown that the overall glucose response (measured as area under the curve during meal challenge) is unchanged after RYGB surgery, 11, 12 but with a leftward shift of the trajectory of plasma glucose, indicating a more rapid absorption and clearance. A recent study shows strong correlation between fasting plasma branched-chain (BC) amino acids (AAs) and insulin sensitivity after RYGB surgery, 12 suggesting that postprandial handling of nutrients other than glucose (ie, AAs and fatty acids) might be altered after RYGB surgery.
The aim of this study was to compare metabolic responses to a meal challenge after RYGB surgery with CR in morbidly obese diabetic patients. Our broader goal was to determine whether metabolite profiles might help explain the exaggerated hormonal responses seen after RYGB surgery and provide insights into mechanisms underlying increased susceptibility to hypoglycemia after RYGB surgery.
METHODS
We recruited 10 obese subjects from the Duke Metabolic and Weight Loss Surgery Program who underwent laparoscopic RYGB surgery. Ten control subjects matched for age, sex, and body mass index were recruited by advertisement and enrolled into the CR group. Exclusion criteria included diabetes duration of more than 5 years, glycated hemoglobin or glycohemoglobin A 1c more than 10%, use of insulin-or incretin-based therapy, previous esophageal, gastric, pancreatic, or bowel surgery, tobacco use, or known substance abuse within 6 months of enrollment. All subjects provided informed consent, and the Duke University Institutional Review Board approved the protocol. discontinued 3 days before mixed-meal tolerance (MMT) test per study protocol. During each visit, subjects consumed 230 kcal of liquid meal of 8 oz of Ensure High Protein. The liquid supplement was provided to the subjects at 5-minute intervals over a total of 20 minutes to accommodate for the reduced gastric capacity of subjects after RYGB surgery. Blood samples were collected before meal ingestion and at 30, 60, 90, and 120 minutes after completion of the meal.
Upon hospital discharge, RYGB surgery subjects consumed a standard liquid diet provided by the surgery program. The CR subjects were instructed to consume similar diet that matched RYGB surgery subjects. Four 8-oz cans of Ensure High Protein were given daily to each subject to provide 920 kcal per day. Dietary intake was monitored in all subjects by fluid intake records from admission to the study through to the postintervention visit. All antidiabetic medications were stopped after RYGB surgery, stopped for 5 CR subjects, and reduced by 50% in the remaining subjects.
Surgical Procedure
Briefly, a small proximal gastric pouch (∼30 mL) was created. The jejunum was divided at 50 cm distal to the ligament of Treitz, and a 2-cm end-to-side gastrojejunostomy was performed. A side-to-side jejunojejunostomy was then created 100 cm distal to the gastrojejunostomy. There were no postoperative complications, and all subjects were discharged between postoperative days 1 and 3.
Analytical Procedures
Blood glucose was measured using the hexokinase method (Beckman, Fullerton, CA). Hormonal analytes were measured in duplicates using the Millipore MILLIPLEX Human Metabolic Hormone Panel, based on the Luminex xMAP technology. The intra-and interassay coefficients of variation for the analytes were less than 8% and less than 16%, respectively. Conventional metabolites, including nonesterified fatty acids (NEFAs), total ketones, β-hydroxybutyrate, and lactate, were measured as previously described. 13 Plasma fibroblast growth factor-21 was measured using an ELISA kit (R&D Systems, Minneapolis, MN) and glucagon using radioimmunoassay (Millipore, Billerica, MA). Plasma acylcarnitines and AAs were measured by tandem mass spectrometry. 14 
Statistical Analysis
All values represent means ± standard error, unless otherwise stated. Statistical analyses were carried out using SPSS ver. 17 (SPSS Inc, Chicago, IL), with P < 0.05 considered as significant. Linear mixed models with random effects were used to analyze postprandial metabolite trajectories in relation to intervention groups and the follow-up period. 5 Linear mixed-effects estimation was carried out with the use of restricted maximum likelihood methods. The postprandial time was treated as a categorical factor to represent longitudinal patterns observed in each metabolite measurement. 16 The main effect of the analysis modeled the mean metabolite response over time during the MMT test. Interaction terms were included to examine the impact of intervention (CR and RYGB surgery) on the postprandial trajectories. Comparisons of mean metabolite concentrations were conducted using Student t tests. We performed cross-correlation analysis (described in Supplemental Digital Content Appendix, available at http://links.lww.com/SLA/A399) to assess the interrelationship between changes in metabolites and hormones of interest. 17 
RESULTS
Changes in body mass index, insulin sensitivity, and hormone levels for the RYGB surgery and CR groups are described in Supplemental Digital Content Appendix (available at http://links.lww. com/SLA/A399). There was no difference in the percentage change in body mass index, fasting glucose, and insulin sensitivity between groups. The percentage weight loss was greater with RYGB surgery than with CR (−8.3 ± 0.5 kg vs −4.3 ± 0.6 kg, P < 0.001). Thus, body weight was included as a covariate in the following analyses to account for differences between the 2 intervention groups.
Percentage Change in Metabolites From

Pre-to Postintervention
There were no significant differences in plasma AA levels between the CR and RYGB surgery groups preintervention. Significant reductions in fasting proline, histidine, valine, phenylalanine, molar sum of BCAA, aromatic AAs, and total AAs were observed after RYGB surgery ( Table 1 , left column) but not with CR. Fasting alanine was reduced significantly in both groups.
Consistent with the reduction in fasting total AAs and BCAAs, there was a significant reduction in the molar sum of C3 and C5 acylcarnitines (byproducts of BCAA and other AA catabolism) in both intervention groups. Fasting C2, long-chain (C14-C22), and total acylcarnitines were significantly increased with both interventions. Fasting medium-chain (C6-C12) acylcarnitines were significantly increased in the CR group (P = 0.003) but not in the RYGB surgery group. Both interventions resulted in significant increases in fasting NEFA, total ketone, and β-hydroxybutyrate levels, with a trend toward larger responses with RYGB surgery.
Two hours after the MMT test, significant reductions of 20% to 30% were observed in multiple AAs, molar sum of BCAAs, aromatic AAs, and total AAs in the RYGB surgery group but not in the CR group (Table 1 , right column). Plasma C2, medium-chain, long-chain, and total acylcarnitines were significantly higher at 2-hour post-MMT test after both interventions, with no between-group differences.
Changes in Postprandial AA Trajectories
Overall, the mean postprandial responses for valine, proline, histidine, serine, aspartate, ornithine, citrulline, and BCAA were highly significant after intervention in both groups (all P values . However, the mean postprandial responses for phenylalanine, glycine, glutamate/glutamine, and aromatic AAs were significant with RYGB surgery (all P values <0.05) but not with CR. The postprandial trajectories for valine, leucine/isoleucine, phenylalanine, tyrosine, proline, serine, methionine, and arginine were significantly altered after RYGB surgery (all interaction term P values <0.05) but not after CR.
Next, we examined the differences in the postprandial AA trajectories between the CR and RYGB surgery groups (compare filled circles vs filled squares in Fig. 1 and Supplemental Digital Content Appendix Figure S1 , available at http://links.lww.com/SLA/A399). In the postintervention period, postprandial trajectories for proline, valine, leucine/isoleucine, phenylalanine, tyrosine, ornithine, methionine, and arginine were statistically different between the 2 experimental groups (all interaction term P values <0.05). These AA trajectories were not different between groups in the preintervention period, demonstrating a unique effect of RYGB surgery on the trajectories of these AAs with meal challenge. The post-RYGB surgery trajectories exhibited a steep increase in the first phase (0-60 minutes), with rapid decline in the second phase (60-120 minutes) of the MMT test. Data are expressed as percentage change postintervention relative to preintervention for the CR or RYGB surgery subjects. Data are presented as mean ± standard error. 1 β-hydroxybutyrate were significantly increased with both interventions (all P values <0.05). Changes in the postprandial trajectories for medium-chain acylcarnitines were significant only with CR (P < 0.001).
Changes in Postprandial Glucose and Glucoregulatory Hormones Trajectories
The postprandial trajectories for glucose, insulin, C-peptide, glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon showed a steeper rise after RYGB surgery (all P values <0.05) but not after CR (see Supplementary Digital Content Appendix Figure S2 and S3, available at http://links.lww.com/SLA/A399). The increment in insulin, GIP, and GLP-1 responses from baseline to peak were larger and occurred more rapidly after the MMT test in RYGB surgery than in CR.
Changes in Postprandial Gluconeogenic Substrate Trajectories
The postprandial trajectories for alanine, lactate, and pyruvate tracked significantly lower from pre-to postintervention in both groups (Fig. 3) . However, at the later time points of the MMT test, marked divergence in trajectories were observed post-RYGB surgery versus post-CR for alanine (P < 0.001), lactate (P < 0.001), and pyruvate (P = 0.013) such that levels of these metabolites were much lower in the RYGB surgery group.
Interrelationship Between the Temporal Changes in Metabolites and Gut Hormones
Because temporal changes in metabolites (in particular, glucose and AAs) and gut hormones (in particular, insulin, GIP, and GLP-1) were distinctly different between CR and RYGB surgery, we performed cross-correlation analysis to assess the interrelationship between their postprandial responses. In the RYGB surgery group, leucine/isoleucine and methionine exhibited significant positive cross-correlation ranging from 0.624 to 0.679 at lag no. = −1, indicating that the changes in these AAs led the changes in insulin response (Table 2) . Similarly, changes in GLP-1 led changes in insulin response (lag no. = −1, cross-correlation function = 0.564) in the RYGB surgery group. A positive cross-correlation value at negative lag numbers for tyrosine and glutamate/glutamine and GLP-1 suggests that changes in these AAs led changes in GLP-1 response after RYGB surgery.
DISCUSSION
Although RYGB surgery is known to cause early improvements in glucose homeostasis, this is the first study that reports on a broad spectrum of metabolic changes occurring early after RYGB surgery. The key strength of the study is that subjects were well matched for sex, race, age, and body weight. The CR subjects received controlled amounts of a liquid diet matched to postsurgical subjects in order to achieve similar negative energy balance. We thereby establish that the preferential lowering of BCAA and aromatic AA levels occurs early (2 weeks) after RYGB surgery and is not due to differences in food intake, because unlike previous studies, 12, 18 food intake was controlled in both intervention groups in this study. The changes in metabolites are more pronounced in the postprandial than in the fasted period after RYGB surgery. In addition, the rate of changes in the appearance and clearance of multiple AAs mirror the rate of changes in glucose, insulin, and incretin responses after RYGB surgery. The rate of change for several of these metabolites correlated with and predicted changes in insulin and incretin responses, suggesting a biological link between the rate of changes of these metabolites and the augmented gut hormonal responses. Finally, we observe distinct effects of RYGB surgery on clearance of gluconeogenic substrates after meal challenge. The rapid peak in plasma glucose is consistent with more efficient entry of nutrients into the Roux limb as postulated, 11 but we demonstrate for the first time that this applies to multiple AAs.
Almost all AA levels were significantly lower after RYGB surgery than after CR at the end of meal challenge, implying improved peripheral uptake and utilization of these metabolites. Because the postprandial trajectories of AAs track closely to that of insulin, the enhanced nutrient clearance could be due to increased insulin secretion or improved insulin action, or both. AAs are potent insulin secretagogues, and metabolic clearance of AAs is related to their effectiveness as insulin secretagogues. 19 In this study, changes in leucine/isoleucine, methionine, and phenylalanine levels were correlated with changes in insulin levels after RYGB surgery. Early changes in GLP-1 levels are also correlated with insulin response after RYGB surgery, a relationship that was not seen after CR. 6 Our findings suggest a link between the rapid appearance of AAs and incretin and insulin secretion, agreeing with previous studies that show a synergistic relationship between incretin secretion and AA levels in stimulation of insulin secretion. 20 The exaggerated postprandial incretin response after RYGB surgery may also be due to early and rapid exposure of distal gut to luminal glucose 21 and partial protein hydrolysates. 22 Although alanine, serine, and glutamine have been shown to stimulate GLP-1 release from the Glutag cell line, 23 we found that tyrosine and glutamate/glutamine seem to lead the changes in GLP-1 response to a meal after RYGB surgery. The exact physiological role of these AAs in the regulation of incretin responses is a subject worthy of further investigation.
We also observed that RYGB surgery has a larger impact on lipid metabolism than CR. Multiple intermediates and endpoints of fatty acid oxidation tended to be higher in the fasted state in RYGB surgery subjects. This includes acetylcarnitine (C2), total ketones, β-hydroxybutyrate, and long-chain acylcarnitines. Interestingly, with RYGB surgery, postprandial NEFA levels decline at a rate similar to CR, but levels of end products of fatty acid oxidation, including ketones, decline more slowly. The medium-chain (incompletely oxidized) acylcarnitines levels are higher after CR than after RYGB surgery. We interpret these results to indicate a higher rate and efficiency of fatty acid oxidation after RYGB surgery. Increased catabolism of ketogenic AAs such as leucine may also contribute to the sustained elevation of ketones post-RYGB surgery.
Finally, the postprandial trajectories for alanine, pyruvate, and lactate differ remarkably between CR and RYGB surgery, which could possibly explain the greater susceptibility to hypoglycemia reported for the latter group. 8 Although these key gluconeogenic substrates levels generally increase with CR, they decline after RYGB surgery, and most strikingly toward the conclusion of meal challenge. Prior studies have suggested that β-cell hyperplasia with resultant hyperinsulinemia is the primary cause of hypoglycemia after RYGB surgery. 24 However, plasma glucose and insulin responses to oral glucose in patients with symptomatic hypoglycemia after RYGB surgery are rather similar to responses in individuals who remain asymptomatic. 7 Thus, our finding of exaggerated postprandial insulin responses in RYGB surgery subjects followed by similarly exaggerated clearance for glucose, AAs, lactate, and pyruvate may suggest that the subjects become more reliant on gluconeogenesis to maintain glucose levels after RYGB surgery but now in the face of reduced availability of key gluconeogenic precursors.
The study has several limitations. Static metabolite profiles can identify perturbations in fuel metabolism, but they do not provide definitive information about metabolic flux. Although crosscorrelation analysis suggests that AAs could modulate gut hormone 
Lag no. <0 indicates that metabolite of interest leads the corresponding hormone, lag no. >0 indicates that metabolite of interest lags the corresponding hormone, and lag no. = 0 means that the changes in metabolite and hormone occurs simultaneously. CCF values >0.500 are bold for easy reading. All the values are statistically significant at P < 0.05. We omitted CCF values with P > 0.05.
CCF indicates cross-correlation function.
responses, no direct evidence for a cause-effect relationship was provided. The magnitude of weight loss was slightly greater with RYGB surgery than with CR. Although most of the weight loss during this period is likely due to reduction in total body water, 25 we included body weight as a covariate in our analyses to account for the group differences. Thus, the early and specific adaptive metabolic responses in RYGB surgery compared with CR subjects described herein are independent of the amount of weight lost. Although the postsurgical period might influence the metabolic responses, it is more likely to interfere with, rather than enhance improvement in, glycemic control. Finally, further studies are needed to ascertain whether the findings of postprandial metabolite profiles observed in patients after RYGB surgery are similar to those induced by other bariatric procedures (eg, sleeve gastrectomy).
CONCLUSIONS
A greater disposal of glucose and AAs and more complete β-oxidation of fatty acids are early, and positive changes in metabolic flexibility post-RYGB surgery might contribute to the continuous and sustained improvement in insulin sensitivity in these subjects seen with longer follow-up. The changes in the trajectories of these metabolites is distinct after RYGB surgery and is likely due to enhanced luminal nutrient transit and absorption as a result of structural alterations in the gut anatomy. Findings of a sharp reduction in key gluconeogenic substrates may also help explain the greater susceptibility of RYGB surgery subjects to hypoglycemic symptoms.
